Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RST-500
- Development stage
- Preclinical
- Lead developer
- ReST Therapeutics
- Modality
- Small Molecules
01
Overview
RST-500 is a small molecule NMDA receptor (NMDAR) modulator specifically targeting the GluN2D subunit, currently in preclinical development by ReST Therapeutics. It is being investigated for 'Radiomize,' a radiotherapy-related indication. The drug is part of a molecular platform designed to address NMDAR overactivation in neuropsychiatric and neurodegenerative contexts. By selectively inhibiting or modulating the GluN2D subunit, RST-500 aims to provide neuroprotection and facilitate recovery from stress or injury associated with radiotherapy.
Beyond the preview
Go deeper on RST-500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RST-500.